Literature DB >> 16688934

Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.

Randa K Mahmoud1, Amina K El-Ansary, Hatem H El-Eishi, Haba M Kamal, Nehal H El-Saeed.   

Abstract

OBJECTIVES: To investigate whether serum levels of matrix metalloproteinases (MMP-3, stromelysin) and (MMP-1, collagenase) are specifically elevated in joint disease as rheumatoid arthritis (RA) compared to osteoarthritis (OA), and to assess how these markers reflect the clinical activity of RA compared to circulating cytokine as tumor necrosis factor-alpha (TNF-alpha) as well as established variables as [C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)]. SUBJECTS AND METHODS: This study included 22 patients with RA, 10 patients with OA and 10 healthy control subjects matched for age and sex. Patients with superimposed infection were excluded. Serum levels of MMP-3, MMP-1, TNF-alpha and CRP were assayed. Synovial fluid (SF) levels of MMP-3 and MMP-1 were also assayed.
RESULTS: Serum levels of TNF-alpha and CRP in RA patients were significantly higher than normal subjects. Serum MMP-1 was significantly elevated in patients with RA and OA, compared to healthy controls but there were no significant differences between patients with RA and those with OA. Serum MMP-3 levels did not differ between OA patients and normal sera. However, RA patients displayed significantly elevated levels of this enzyme, compared to OA and control sera. Levels of MMP-3 and MMP-1 in the SF of RA patients were significantly higher than in OA fluids. CRP, ESR, TNF-alpha and MMP-3 correlated significantly with the swollen joint count. The strongest positive correlations existed between rheumatoid activity as assessed by the levels of CRP and circulating levels of MMP-3. Similar correlations between TNF-alpha concentration and CRP, MMP-1 and MMP-3 were observed in RA patients. Serum levels of MMP-3 correlated significantly with serum concentrations of MMP-1 in RA patients (r = 0.487, p < 0.05). There was close correlation between serum and SF concentrations of MMP-3 in RA patients (r = 0.619, p < 0.01). In the same patients there was highly significant correlation between SF concentrations of MMP-3 and MMP-1 (r = 0.732, p < 0.001).
CONCLUSIONS: Our data suggested that elevated MMP-3 levels reflected disease activity of RA better than cytokine levels. However, MMP-3 levels do not exceed the association of CRP with clinical activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16688934

Source DB:  PubMed          Journal:  Ital J Biochem        ISSN: 0021-2938


  14 in total

1.  Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis.

Authors:  K A Kimmerling; B D Furman; D S Mangiapani; M A Moverman; S M Sinclair; J L Huebner; A Chilkoti; V B Kraus; L A Setton; F Guilak; S A Olson
Journal:  Eur Cell Mater       Date:  2015-01-31       Impact factor: 3.942

2.  Injection of AAV2-BMP2 and AAV2-TIMP1 into the nucleus pulposus slows the course of intervertebral disc degeneration in an in vivo rabbit model.

Authors:  Steven K Leckie; Bernard P Bechara; Robert A Hartman; Gwendolyn A Sowa; Barrett I Woods; Joao P Coelho; William T Witt; Qing D Dong; Brent W Bowman; Kevin M Bell; Nam V Vo; Bing Wang; James D Kang
Journal:  Spine J       Date:  2011-10-22       Impact factor: 4.166

3.  Prospects for treating osteoarthritis: enzyme-protein interactions regulating matrix metalloproteinase activity.

Authors:  Evan Meszaros; Charles J Malemud
Journal:  Ther Adv Chronic Dis       Date:  2012-09       Impact factor: 5.091

4.  Immunolocalization of MMP-2 and MMP-9 in human rheumatoid synovium.

Authors:  Meng Zhou; Si Qin; Yang Chu; Fengming Wang; Lujun Chen; Yahua Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

5.  Matrix metalloproteinase protein expression profiles cannot distinguish between normal and early osteoarthritic synovial fluid.

Authors:  Bryan J Heard; Liam Martin; Jerome B Rattner; Cyril B Frank; David A Hart; Roman Krawetz
Journal:  BMC Musculoskelet Disord       Date:  2012-07-23       Impact factor: 2.362

6.  The role of cyclooxygenase-2, interleukin-1β and fibroblast growth factor-2 in the activation of matrix metalloproteinase-1 in sheared-chondrocytes and articular cartilage.

Authors:  Pei-Pei Guan; Jing-Wen Guo; Xin Yu; Yue Wang; Tao Wang; Konstantinos Konstantopoulos; Zhan-You Wang; Pu Wang
Journal:  Sci Rep       Date:  2015-05-20       Impact factor: 4.379

7.  Morusin Ameliorates IL-1β-Induced Chondrocyte Inflammation and Osteoarthritis via NF-κB Signal Pathway.

Authors:  Yewei Jia; Wei He; Hanxiao Zhang; Lei He; Yanben Wang; Tan Zhang; Jiaxuan Peng; Peng Sun; Yu Qian
Journal:  Drug Des Devel Ther       Date:  2020-03-26       Impact factor: 4.162

8.  Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton's jelly.

Authors:  Paola Romina Amable; Marcus Vinicius Telles Teixeira; Rosana Bizon Vieira Carias; José Mauro Granjeiro; Radovan Borojevic
Journal:  Stem Cell Res Ther       Date:  2014-04-16       Impact factor: 6.832

9.  Serum levels of the proinflammatory cytokine interleukin-6 vary based on diagnoses in individuals with lumbar intervertebral disc diseases.

Authors:  Kathryn T Weber; D Olivier Alipui; Cristina P Sison; Ona Bloom; Shaheda Quraishi; M Chris Overby; Mitchell Levine; Nadeen O Chahine
Journal:  Arthritis Res Ther       Date:  2016-01-07       Impact factor: 5.156

10.  Therapeutic Potential of Sclareol in Experimental Models of Rheumatoid Arthritis.

Authors:  Sen-Wei Tsai; Ming-Chia Hsieh; Shiming Li; Shih-Chao Lin; Shun-Ping Wang; Caitlin W Lehman; Christopher Z Lien; Chi-Chien Lin
Journal:  Int J Mol Sci       Date:  2018-05-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.